Cencora Executive Compensation (FY25)
COR · Executive and director compensation, fiscal 2022 to 2025
The Cencora brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): March 6, 2026
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
308 figures on this page: 300 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Mauch: $9,253,192 → $18,256,227 (97.3% higher)
CEO pay ratio: 210:1 → 198:1 (5.7% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Cencora's chief executive and what were they paid?
Robert Mauch was paid $18,256,227 in total compensation as President and Chief Executive Officer for fiscal 2025. Mauch's total moved 97.3% higher from the $9,253,192 reported for fiscal 2024.
What was Cencora's say-on-pay result?
The say-on-pay proposal drew 93.0% of votes cast including abstentions in favor at the meeting held March 5, 2026 for fiscal 2025.
Which companies are in Cencora's peer group?
Companies named in the disclosed peer group include Cardinal Health, Inc., CVS Health Corporation, Eli Lilly and Company, FedEx Corporation and HCA Healthcare, Inc., among others.
What is Cencora's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 198:1, against median employee compensation of $92,438.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Steven Collis Chairman, President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Robert Mauch Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
James Cleary Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Silvana Battaglia Executive Vice President and Chief Human Resources Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Steven Collis Chairman, President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Robert Mauch Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
James Cleary Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Elizabeth Campbell Executive Vice President and Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Gina Clark Executive Vice President and Chief Communications & Administration Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Silvana Battaglia Executive Vice President and Chief Human Resources Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Steven Collis Chairman, President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Robert Mauch Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
James Cleary Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Elizabeth Campbell Executive Vice President and Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Silvana Battaglia Executive Vice President and Chief Human Resources Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Mauch President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Steven Collis Executive Chairman | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
James Cleary Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Elizabeth Campbell Executive Vice President and Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Silvana Battaglia Executive Vice President and Chief Human Resources Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Elizabeth Campbell | Performance Share | ◇ | — | — | — | — | — | ◇ |
| Elizabeth Campbell | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| James Cleary | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| James Cleary | Performance Share | ◇ | — | — | — | — | — | ◇ |
| Robert Mauch | Performance Share | ◇ | — | — | — | — | — | ◇ |
| Robert Mauch | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Silvana Battaglia | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Silvana Battaglia | Performance Share | ◇ | — | — | — | — | — | ◇ |
| Steven Collis | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Steven Collis | Performance Share | ◇ | — | — | — | — | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Silvana Battaglia | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Elizabeth Campbell | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Robert Mauch | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/13/2026 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| James Cleary | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/13/2026 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Steven Collis | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 11/13/2026 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Elizabeth Campbell
Executive Vice President and Chief Legal Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
James Cleary
Executive Vice President and Chief Financial Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
Robert Mauch
President and Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
Silvana Battaglia
Executive Vice President and Chief Human Resources Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
Steven Collis
Executive Chairman · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Frank K. Clyburn | ◇ | ◇ | — | — | — | — | ◇ |
Redonda G. Miller, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Werner Baumann | ◇ | ◇ | — | — | — | — | ◇ |
D. Mark Durcan Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Lauren M. Tyler | ◇ | ◇ | — | — | — | — | ◇ |
Dennis M. Nally | ◇ | ◇ | — | — | — | — | ◇ |
Lon R. Greenberg | ◇ | ◇ | — | — | — | — | ◇ |
Lorence H. Kim, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Lori J. Ryerkerk | ◇ | ◇ | — | — | — | — | ◇ |
Kathleen W. Hyle | ◇ | — | — | — | — | — | ◇ |
Richard W. Gochnauer | ◇ | — | — | — | — | — | ◇ |
Ellen G. Cooper, Ornella Barra, Robert P. Mauch and Steven H. Collis served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Equity is delivered as restricted stock units.
Stock ownership guideline: 5 times annual cash retainer
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Cardinal Health, Inc. CAH
- CVS Health Corporation CVS
- Eli Lilly and Company LLY
- FedEx Corporation FDX
- HCA Healthcare, Inc. HCA
- Henry Schein, Inc. HSIC
- Humana Inc. HUM
- IQVIA Holdings Inc. IQV
- Labcorp Holdings Inc. LH
- McKesson Corporation MCK
- Quest Diagnostics Incorporated DGX
- Sysco Corporation SYY
- Target Corporation TGT
- The Cigna Group CI
- The Kroger Co. KR
- United Parcel Service, Inc. UPS
- Viatris Inc. VTRS
- Walgreens Boots Alliance, Inc. WBA
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | March 5, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | March 6, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | March 12, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | March 9, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | March 10, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | March 11, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | March 5, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | February 28, 2019 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Cencora disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Cencora sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
308 figures on this page: 300 cited to the filing that reported them, 8 calculated from figures it prints.
300 cited to the filing
8 calculated from the filing
Documents cited
- 0001140859-26-000014Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-26-003061CEO Pay Ratio · Director compensation · Fiscal 2025 director compensation · Grants of Plan-Based Awards · and 2 more sections
- 0001104659-25-022205
- 0001140859-25-000017Summary Compensation Table
- 0001104659-24-035043
- 0001104659-24-007747Summary compensation table
- 0001140859-23-000077
- 0001104659-23-007236Executive compensation tables · Summary Compensation Table
- 0001140859-22-000011
- 0001140859-21-000015
- 0001140859-20-000013
- 0001140859-19-000010
- 0001140859-19-000002
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Cencora executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/COR (accessed 2026).
Short form: data: Velarion
The Cencora brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Cencora and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Cencora discloses
The companies named in COR's own disclosed peer group.
Cardinal Health, Inc.CVS Health CorporationEli Lilly and CompanyFedEx CorporationHCA Healthcare, Inc.Henry Schein, Inc.Humana Inc.IQVIA Holdings Inc.Labcorp Holdings Inc.McKesson CorporationQuest Diagnostics IncorporatedSysco CorporationTarget CorporationThe Cigna GroupThe Kroger Co.United Parcel Service, Inc.Viatris Inc.Walgreens Boots Alliance, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}